Comparison of Different Rabbit Anti-Thymocyte Globulin Formulations in the Prophylaxis of Graft-Versus-Host Disease: A Systematic Review

Allogeneic hematopoietic stem cell transplantation (allo-HCT) is a potentially curative treatment modality, frequently used for patients suffering from haematological malignancies. In the last two decades, there have been multiple randomised controlled trials (RCTs), review articles, and meta-analyses addressing efficacy of rabbit anti-thymocyte globulin (r-ATG) as graft-versus-host disease (GvHD) prophylaxis. Nevertheless, only few aimed to compare effectiveness different r-ATG formulations. Since article we retrieved comparing r-ATGs in GvHD prophylaxis dates back 2017, performed systematic literature articles published since 2017 this day, utilising PubMed, Scopus, Cochrane, MEDLINE, with main endpoints being acute (aGvHD) chronic (cGvHD). We subjected scrutiny total five studies, which four compared differences between Thymoglobulin (ATG-T) Grafalon (ATG-G), one discussed impact ATG-T dose. Overall, cGvHD, aGvHD grades II–IV, TRM, OS, NRM, LFS, relapse, overall infections, EBV reactivation do not seem be affected by type utilised rATG. However, data on III–IV, GRFS, moderate–severe CMV conflicting. Through our research, sought summarise most recent findings concerning allo-HCT, provide insight into targets origin various ATG